Key Takeaway: The article discusses a poster presentation at the AD/PD 2024 conference, detailing a plasma proteomic analysis from Alzheimer's patients involved in the SPARC clinical trial. The study aims to identify pharmacodynamic biomarkers for the S2R modulator CT1812. This research could enhance understanding of Alzheimer's treatment efficacy.
Price reaction · baseline $1.94 (2024-03-04 close) · hit pre-market · 1 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+8.2%
day 1
+5.2%
day 3
+1.5%
Market Sentiment Analysis
POSITIVE FACTORS
Identification of pharmacodynamic biomarkers is promising.
The study focuses on Alzheimer's, a critical area of research.
Presentation at a major conference highlights the significance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Lizama B, Duong D, Pandey K, et al. Plasma Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812 . Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference ; Lisbon, Portugal.
Frequently Asked Questions
What was presented at the AD/PD 2024 conference?
A poster on plasma proteomic analysis from Alzheimer's patients in the SPARC trial.
What is the focus of the SPARC clinical trial?
The trial aims to identify pharmacodynamic biomarkers for the S2R modulator CT1812.
Who are the authors of the study?
The study was authored by Lizama B, Duong D, Pandey K, and others.